Company news
Harrow, Inc. news in 2025
Harrow, Inc.'s news releases, calls and decks from 2025, newest first.
Harrow to Present at Two Investor Conferences in December
November 23, 2025
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
November 17, 2025
Harrow Announces Third Quarter 2025 Financial Results
November 9, 2025
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
October 26, 2025
ImprimisRx Announces Leadership Changes
October 5, 2025
Harrow to Acquire Melt Pharmaceuticals
September 25, 2025
Harrow Launches Harrow Access for All (HAFA)
September 24, 2025
Harrow Announces Agenda and Speakers for Investor & Analyst Day
September 14, 2025
Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
September 7, 2025
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
September 7, 2025
Harrow Announces Second-Quarter 2025 Financial Results
August 10, 2025
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
August 5, 2025
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
July 28, 2025
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
July 16, 2025
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
June 17, 2025
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
June 8, 2025
Harrow to Present at Two Investor Conferences in May
May 13, 2025
Harrow Announces First-Quarter 2025 Financial Results
May 7, 2025
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
May 4, 2025
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
April 23, 2025
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
April 9, 2025
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
March 26, 2025
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
March 26, 2025
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
March 23, 2025
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
March 16, 2025
Harrow Launches VEVYE® Access for All
March 16, 2025
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
March 10, 2025
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
March 2, 2025
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
January 26, 2025
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
January 6, 2025
Calls in 2025
Decks in 2025
- Investor Presentation (November 2025)
Investor deck · 37 slides · Nov 10, 2025
- Investor Day (September 2025)
Investor day · 117 slides · Sep 26, 2025
- Q2 2025 Earnings Presentation
Earnings · 28 slides · Aug 12, 2025
- Q1 2025 Earnings Presentation
Earnings · 13 slides · May 9, 2025
- Investor Presentation (March 2025)
Investor deck · 13 slides · March 2025